At the meeting of the International Society of Nucleic Acid Immunity and at the Immunobiology of Viral Infections conference this month, researchers from Klinikum Der Universitat Munchen - KUM (Maria Bengoa, Simon Rothenfusser, Helen Stirling) presented groundbreaking findings on how pre-existing immunity to Tick-Borne Encephalitis Virus (TBEV) can enhance the immunogenicity of the Yellow Fever 17D (YF17D) vaccine through antibody-dependent enhancement (ADE).
This research demonstrates that prior immunity to TBEV boosts the immune response to the YF17D vaccine through the activation of alternative sensing pathways, and increases the potential for cross-reactivity with dengue (DENV) and Zika (ZIKV) viruses in the presence of TBEV-specific antibodies. This underscores the importance of considering past flavivirus exposures, as they may influence immune responses and vaccine efficacy.
This research underscores the importance of understanding immune responses to improve vaccination approaches and public health outcomes in an increasingly interconnected world.
Comments